Lucid Capital Markets Starts Passage Bio Inc. (PASG) at Buy, PT $68 Nov 24, 2025 06:36AM
Passage Bio Inc. (PASG) PT Lowered to $10 at Guggenheim Aug 14, 2025 06:57AM
Passage Bio Inc. (PASG) PT Lowered to $67 at Canaccord Genuity Aug 14, 2025 06:43AM
Passage Bio announces 1-for-20 reverse stock split effective July 14 Jul 10, 2025 07:01AM
Passage Bio (PASG) Reports Updated Interim Data from upliFT-D Study and Provides Program Update Jun 23, 2025 07:01AM


May 13, 2025 05:43PM Passage Bio, Inc. (PASG) Reports In-Line Q1 EPS
Mar 4, 2025 04:13PM Passage Bio Inc. (PASG) PT Lowered to $6 at Chardan Capital Markets
Jan 10, 2025 07:11AM Passage Bio (PASG) Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates
Nov 13, 2024 04:30PM Passage Bio, Inc. (PASG) Misses Q3 EPS by 8c
Oct 24, 2024 07:02AM Passage Bio (PASG) Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN
Oct 24, 2024 07:00AM Passage Bio (PASG) Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN
Sep 17, 2024 06:42AM Canaccord Genuity Reiterates Buy Rating on Passage Bio Inc. (PASG)
Sep 10, 2024 07:53AM Passage Bio (PASG) Welcomes Tom Kassberg to Board of Directors
Aug 8, 2024 08:46AM Passage Bio, Inc. (PASG) Tops Q2 EPS by 5c
Aug 1, 2024 07:05AM Passage Bio (PASG) Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration
Jul 16, 2024 07:00AM Passage Bio (PASG) Receives Positive FDA Feedback on Expansion of upliFT-D Trial of PBFT02